HCPLive Network

Glucagonlike Peptide 1 Therapies Increase Pancreatitis Risk

THURSDAY, Feb. 28 (HealthDay News) -- Use of glucagonlike peptide 1 (GLP-1)-based therapies (GLP-1 mimetic, exenatide, and dipeptidyl peptidase 4 inhibitor, sitagliptin phosphate) correlates with increased likelihood of hospitalization for acute pancreatitis among adults with type 2 diabetes, according to a study published online Feb. 25 in JAMA Internal Medicine.

Sonal Singh, MD, MPH, from Johns Hopkins University School of Medicine, in Baltimore, and colleagues conducted a population-based study using data from a large U.S. administrative database (Feb. 1, 2005 through Dec. 31, 2008). Using a validated algorithm, they identified 1,269 adults with type 2 diabetes, hospitalized with acute pancreatitis, who were matched for age, sex, and diabetes complications with 1,269 control subjects.

The researchers found that cases were significantly more likely to have hypertriglyceridemia, alcohol use, gallstones, tobacco abuse, obesity, biliary and pancreatic cancer, cystic fibrosis, and any neoplasm, compared with controls. Relative to nonusers, the odds of acute pancreatitis were significantly increased for those with current use of GLP-1-based therapies within 30 days (adjusted odds ratio, 2.24) and recent use past 30 days and less than two years (adjusted odds ratio, 2.01), after adjustment for other confounding variables including metformin hydrochloride use.

"In this administrative database study of U.S. adults with type 2 diabetes mellitus, treatment with the GLP-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalization for acute pancreatitis," write the authors.

The original development of the dataset used in this study was funded by grants from the pharmaceutical and medical device industries.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
As more studies have demonstrated potential therapeutic applications for marijuana, public opinion regarding medical and recreational marijuana use has shifted. One such study recently published in the American Journal of Gastroenterology revealed medical marijuana is potentially beneficial for digestive disorders and gastrointestinal symptoms.
Enterovirus-D68 could soon be in the rearview mirror, according to a Hartford, CT, pediatric intensivist who has treated more than 20 children hospitalized with the infection. “We may have plateaued,” said Christopher Carroll, MD, an asthma specialist at Connecticut Children’s Medical Center. While children are still being admitted for respiratory problems, “Now it’s more a mix of symptoms, not those of classic enterovirus.” Though he could not say for certain the outbreak has peaked, he did say that “things are not continuing to get worse.”
The World Health Organization continued its efforts to battle the ongoing Ebola outbreak with a second meeting of its Emergency Committee tackling the virus.
Counseling at-risk teens and adults to change risky behavior is an effective way to reduce the spread of sexually transmitted diseases, according to the US Preventive Services Task Force (USPSTF). The group is updating its guidelines for primary care physicians to recommend they offer appropriate patients such behavioral advice. The task force also calls for routine screening for chlamydia and gonorrhea for sexually active teens and women up to age 24. Older women who are pregnant or may be at risk of infection due to a variety of sexual behaviors—such as having multiple partners or exchanging sex for money or drugs—should also be screened, the USPSTF said.
Advances in knowledge surrounding gastrointestinal conditions have paved the way for improvements in Crohn’s disease (CD) treatment. To aid clinicians in managing patients with CD, the American Gastroenterological Association (AGA) created a clinical decision tool to effectively guide gastroenterologists throughout their decision-making process.
Smokers with cancer who used e-cigarettes along with traditional cigarettes were more dependent on nicotine than those who didn't use the devices, a Memorial Sloan Kettering study found. These patients were also just as likely -- or less likely -- to have quit smoking than patients who didn't use e-cigarettes.
In acute lymphoblastic leukemia, tumor vulnerability to different chemotherapeutic agents varies at different stages of clonal evolution, which could represent a viable strategy in avoiding drug resistance. These findings were presented at the American Association for Cancer Research's special conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies, held from Sept. 20 to 23 in Philadelphia.
More Reading